Rigel Pharmaceuticals (RIGL) Aperçu de l'action
Rigel Pharmaceuticals, Inc. est une société de biotechnologie qui développe et fournit des thérapies qui améliorent la vie des patients atteints de troubles hématologiques et de cancer aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 2/6 |
| Performances passées | 5/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
RIGL Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Rigel Pharmaceuticals, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$42.58 |
| Plus haut sur 52 semaines | US$52.24 |
| Plus bas sur 52 semaines | US$24.95 |
| Bêta | 1.17 |
| Variation sur 1 mois | 5.03% |
| Variation sur 3 mois | 48.83% |
| Variation sur 1 an | 7.77% |
| Variation sur 3 ans | 273.51% |
| Variation sur 5 ans | 16.66% |
| Évolution depuis l'introduction en bourse | -93.35% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Aug 15
RIGL: Future Returns Will Reflect New Breast Cancer Franchise Expansion
Analysts have raised their price target on Rigel Pharmaceuticals from $57 to $85, citing the addition of Veppanu as a fourth U.S. commercial product and the broader ex-U.S. opportunity from the Kissei partnership as key reasons for the reassessment. Analyst Commentary Analysts covering Rigel Pharmaceuticals are focusing on the addition of Veppanu in the U.S. and the ex U.S. potential of Rezlidhia under the Kissei partnership when they frame upside and risk to the current valuation.Seeking Alpha • Aug 05
Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)
Summary Rigel's Q2 beat big ($78.7M revenue, $0.88 EPS), driven by TAVALISSE, but GAVRETO's year-over-year decline is concerning. Guidance raise came from contract revenue, not accelerating core product sales; net product sales guidance unchanged. VEPPANU is strategically sound but adds only incremental value after upfront payments, milestones, and high royalties. Valuation hinges on navigating TAVALISSE's 2032 LOE; downgrading to Hold after the ~50% rally. Read the full article on Seeking AlphaRecent updates
Mise à jour du récit • Aug 15
RIGL: Future Returns Will Reflect New Breast Cancer Franchise Expansion
Analysts have raised their price target on Rigel Pharmaceuticals from $57 to $85, citing the addition of Veppanu as a fourth U.S. commercial product and the broader ex-U.S. opportunity from the Kissei partnership as key reasons for the reassessment. Analyst Commentary Analysts covering Rigel Pharmaceuticals are focusing on the addition of Veppanu in the U.S. and the ex U.S. potential of Rezlidhia under the Kissei partnership when they frame upside and risk to the current valuation.Seeking Alpha • Aug 05
Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)
Summary Rigel's Q2 beat big ($78.7M revenue, $0.88 EPS), driven by TAVALISSE, but GAVRETO's year-over-year decline is concerning. Guidance raise came from contract revenue, not accelerating core product sales; net product sales guidance unchanged. VEPPANU is strategically sound but adds only incremental value after upfront payments, milestones, and high royalties. Valuation hinges on navigating TAVALISSE's 2032 LOE; downgrading to Hold after the ~50% rally. Read the full article on Seeking Alpha
Mise à jour du récit • Jun 30
RIGL: Veppanu In Licensing And Ex U.S. Breast Cancer Expansion Will Drive Repricing
Rigel Pharmaceuticals' fair value estimate has been revised to $81 from $71 as analysts factor in the Veppanu in-licensing and the broader ex U.S. Rezlidhia opportunity in their updated assumptions. Analyst Commentary Recent research coverage on Rigel Pharmaceuticals has centered on the Veppanu in-licensing and the expanding ex U.S. opportunity for Rezlidhia, with several bullish analysts highlighting these moves as key drivers in their updated views on valuation and execution risk.
Mise à jour du récit • Jun 16
RIGL: Breast Cancer Launch Will Drive Future Upside Potential
Analysts nudged their price target on Rigel Pharmaceuticals higher to $81 from $69, citing the Veppanu in-licensing agreement and the expanding Rezlidhia partnership footprint as key drivers behind their updated view. Analyst Commentary Recent research on Rigel Pharmaceuticals has centered on two main themes: the expanding reach of Rezlidhia outside the U.S. and the Veppanu licensing deal with Pfizer and Arvinas.Mise à jour du récit • Jun 02
RIGL: Breast Cancer Launch And Ex U S Expansion Will Shape Future Upside
Analysts raised their price targets on Rigel Pharmaceuticals, including Citi's increase from $69 to $81 per share. They cited the Veppanu in-licensing and the Rezlidhia ex U.S. NDA as key reasons for their revised views.Mise à jour du récit • May 13
RIGL: Execution On Breast Cancer Franchise Will Shape Future Upside Potential
Analysts trimmed their price target on Rigel Pharmaceuticals by $2 as they factor in updated views on growth, profitability and future P/E multiples, even while recent commentary suggests Pfizer's handoff of Veppanu to Rigel could support the company's long term positioning. Analyst Commentary Recent Street views on Rigel Pharmaceuticals highlight a mix of longer term opportunity around Veppanu and nearer term caution on execution, growth visibility and valuation.Article d’analyse • May 12
Statutory Earnings May Not Be The Best Way To Understand Rigel Pharmaceuticals' (NASDAQ:RIGL) True Position
The latest earnings release from Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) disappointed investors. We did some...Mise à jour du récit • Apr 29
RIGL: Higher Future P/E And RIPK1 Rights Will Drive Bullish Repricing
Analysts have modestly adjusted their price target on Rigel Pharmaceuticals, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. However, the headline fair value estimate remains at $71.00.Mise à jour du récit • Apr 14
RIGL: Margin And Revenue Execution Will Shape Future Upside Potential
Analysts recently lifted their price target on Rigel Pharmaceuticals by $2 to reflect updated views on the discount rate, expected revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research commentary highlights that the updated price target reflects new assumptions around discount rates, revenue potential, profit margins, and future P/E levels, but not all of this feedback is upbeat.Mise à jour du récit • Mar 31
RIGL: Higher Future P/E Assumptions Will Support Bullish Repricing
Analysts have raised their price target on Rigel Pharmaceuticals by $2, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish analysts describe the latest US$2 increase in the price target as a reflection of refreshed assumptions on discount rates, revenue potential, and profitability for Rigel Pharmaceuticals.Mise à jour du récit • Mar 17
RIGL: Margin Improvement Execution Will Shape Future Upside Potential
Analysts have increased their price target on Rigel Pharmaceuticals by $2, reflecting updated views on slightly adjusted growth assumptions, a modestly higher discount rate, and expectations for improved profit margins alongside a lower future P/E. Analyst Commentary Recent research around Rigel Pharmaceuticals points to a mixed setup, where the updated price target and refined assumptions are paired with a clear emphasis on execution and margin discipline.Mise à jour du récit • Mar 03
RIGL: Future Returns Will Reflect Elevated 2026 Guidance And Lower Risk Profile
Analysts have lifted their price target on Rigel Pharmaceuticals by $2, citing updated assumptions around long term revenue growth, profit margins, discount rates, and a higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price target as a reflection of confidence in Rigel Pharmaceuticals' long term revenue potential and its ability to convert that into earnings over time.Mise à jour du récit • Feb 17
RIGL: Updated Earnings Outlook And P/E Assumptions Will Drive Bullish Repricing
Analysts have lifted their fair value estimate for Rigel Pharmaceuticals by $2 to $71, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions reflected in recent Street research. Analyst Commentary Recent Street research around Rigel Pharmaceuticals has leaned positive, with bullish analysts using the higher fair value estimate and updated P/E assumptions to support their case for upside potential.Mise à jour du récit • Feb 03
RIGL: Higher 2025 Sales Guidance And Execution Will Shape Future Upside And Risks
Analysts have lifted their fair value estimate for Rigel Pharmaceuticals from $23 to $38 per share, pointing to raised Street price targets, stronger recent product sales versus expectations, higher 2025 sales guidance in the US$225m to US$230m range, solid commercial execution, improving profitability assumptions and a higher future P/E multiple. Analyst Commentary Recent Street research has highlighted Rigel Pharmaceuticals' stronger product sales versus expectations and higher 2025 net product sales guidance in the US$225m to US$230m range, alongside raised price targets in some cases.Mise à jour du récit • Jan 19
RIGL: Future Returns Will Reflect Raised 2025 Sales Guidance And Positive Cash Flow
Analysts have nudged their fair value estimate for Rigel Pharmaceuticals slightly higher to US$51.60 from US$51.20, citing recent price target increases and upgrades that highlight strong commercial execution, improved 2025 net product sales guidance to US$225m to US$230m, positive cash flow, and potential for further business development. Analyst Commentary Recent Street research around Rigel Pharmaceuticals has focused on how the company is executing against its guidance and what that might mean for valuation.Article d’analyse • Jan 08
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Mise à jour du récit • Jan 05
RIGL: Future Returns Will Reflect Stronger Execution And Raised 2025 Sales Guidance
Analysts nudged their fair value estimate for Rigel Pharmaceuticals higher from US$49.60 to US$51.20, citing stronger Q3 product sales, increased 2025 net product sales guidance to US$225m to US$230m, improved profit margin assumptions and a slightly lower future P/E multiple following recent research upgrades. Analyst Commentary Recent research updates point to a constructive shift in sentiment around Rigel Pharmaceuticals, driven by Q3 performance and revised 2025 guidance.Mise à jour du récit • Dec 20
RIGL Q3 Execution And 2025 Guidance Will Drive Bullish Repricing
Analysts have raised their price target on Rigel Pharmaceuticals by about $2 to reflect stronger expected revenue growth, higher profit margins, and improved commercial execution highlighted by recent Street research. Analyst Commentary Bullish analysts have highlighted Rigel Pharmaceuticals as a compelling growth story in the mid-cap biotech space, pointing to recent guidance increases and stronger than expected product sales as key drivers of renewed enthusiasm.Mise à jour du récit • Dec 06
RIGL: Future Results Will Reflect Sustained Execution Amid Emerging Commercial And Pipeline Milestones
Analysts have raised their price target for Rigel Pharmaceuticals by $3, increasing it to $49.60 from $46.60. This change reflects increased confidence in stronger revenue growth, higher profit margins and solid commercial execution highlighted in recent research.Article d’analyse • Nov 27
If EPS Growth Is Important To You, Rigel Pharmaceuticals (NASDAQ:RIGL) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Mise à jour du récit • Nov 22
RIGL: Future Results Will Reflect Continued Strong Commercial Execution Performance
Analysts have raised their price target for Rigel Pharmaceuticals from $45.40 to $46.60. They cite stronger-than-expected product sales, improved profit margins, and continued commercial execution as key factors behind the positive outlook.Article d’analyse • Nov 12
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shareholders would be excited to see that the share price has had a great...Mise à jour du récit • Nov 07
RIGL: Strong Commercial Execution Will Drive Momentum As Upside Is Forecast
Analysts have raised their price target for Rigel Pharmaceuticals from approximately $38.33 to $45.40. They cite improved revenue growth, expanding profit margins, and stronger commercial execution following the company’s better-than-expected sales results and increased future guidance.Article d’analyse • Sep 25
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 23% Discount?
Key Insights The projected fair value for Rigel Pharmaceuticals is US$39.23 based on 2 Stage Free Cash Flow to Equity...Article d’analyse • Sep 25
Benign Growth For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Underpins Stock's 26% Plummet
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shares have retraced a considerable 26% in the last month, reversing a fair...Article d’analyse • Sep 03
Does Rigel Pharmaceuticals (NASDAQ:RIGL) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Mise à jour du récit • Aug 07
Expansion And Clinical Pipeline Will Drive Future Opportunities Despite Risks
Despite a marked slowdown in consensus revenue growth forecasts, a significant improvement in net profit margin has driven the consensus analyst price target for Rigel Pharmaceuticals up from $33.74 to $36.83. What's in the News Raised 2025 total revenue guidance to $270–280 million (from $200–210 million), with net product sales of $210–220 million and collaboration contract revenues of $60 million (from $15–18 million).Article d’analyse • Aug 06
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 28%
NasdaqGS:RIGL 1 Year Share Price vs Fair Value Explore Rigel Pharmaceuticals's Fair Values from the Community and...Article d’analyse • May 15
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Compensation Looks Acceptable To Us And Here's Why
Key Insights Rigel Pharmaceuticals will host its Annual General Meeting on 22nd of May Total pay for CEO Raul Rodriguez...Article d’analyse • May 09
Rigel Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) defied analyst predictions to release its first-quarter results, which were...Article d’analyse • Apr 02
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26%
The Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) share price has softened a substantial 26% over the previous 30 days...Seeking Alpha • Mar 11
Rigel Looks Interesting, But Let's Wait For A Lower Price
Summary Rigel Therapeutics has expanded its oncology portfolio with REZLIDHIA and GAVRETO, alongside its original molecule TAVALISSE for chronic immune thrombocytopenia. The company’s IRAK1/4 inhibitor R289 shows promising preliminary data in lower-risk myelodysplastic syndromes, with good safety and efficacy profiles. Rigel has a strong financial position with a market cap of $366mn, $77mn cash, and projected 2025 revenue of $200-$210 million. Despite positive financials and promising drug data, since RIGL is trading at a 52-week high, I recommend waiting for a lower price to buy. Read the full article on Seeking AlphaRendement pour les actionnaires
| RIGL | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 6.0% | 0.5% | 0.6% |
| 1Y | 7.8% | 35.8% | 20.1% |
Rendement vs Industrie: RIGL a sous-performé le secteur US Biotechs qui a rapporté 35.8 % au cours de l'année écoulée.
Rendement vs marché: RIGL a sous-performé le marché US qui a rapporté 20.1 % au cours de l'année écoulée.
Volatilité des prix
| RIGL volatility | |
|---|---|
| RIGL Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: RIGL n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de RIGL ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1996 | 173 | Raul Rodriguez | www.rigel.com |
Rigel Pharmaceuticals, Inc. est une société de biotechnologie qui développe et fournit des thérapies qui améliorent la vie des patients atteints de troubles hématologiques et de cancer aux États-Unis. La société propose TAVALISSE, un inhibiteur de la tyrosine kinase de la rate administré par voie orale pour le traitement des patients adultes atteints de thrombocytopénie immunitaire chronique ; REZLIDHIA, une monothérapie non intensive pour traiter les patients adultes atteints de leucémie myéloïde aiguë (LMA) récurrente ou réfractaire (R/R) présentant une mutation sensible de l'isocitrate déshydrogénase-1 (IDH1), détectée par un test approuvé par la FDA ; et GAVRETO, un inhibiteur de kinase oral à petite molécule administré une fois par jour pour le traitement des patients adultes atteints d'un cancer du poumon non à petites cellules (CPNPC) métastatique réarrangé au cours de la transfection (RET), ainsi que pour le traitement des patients adultes et pédiatriques âgés de douze ans et plus atteints d'un cancer de la thyroïde avancé ou métastatique positif à la fusion RET. Elle développe également le R289, un inhibiteur oral des kinases 1 et 4 associées aux récepteurs de l'interleukine (IRAK1/4), qui fait l'objet d'une étude de phase 1b pour le traitement des maladies hématologiques-oncologiques, auto-immunes et inflammatoires, ainsi que pour le traitement du syndrome myélodysplasique à faible risque.
Rigel Pharmaceuticals, Inc. Résumé des fondamentaux
| RIGL statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$795.39m |
| Bénéfices(TTM) | US$321.91m |
| Recettes(TTM) | US$276.79m |
2.5x
Ratio P/E2.9x
Ratio P/SLe site RIGL est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| RIGL compte de résultat (TTM) | |
|---|---|
| Recettes | US$276.79m |
| Coût des recettes | US$67.51m |
| Marge brute | US$209.27m |
| Autres dépenses | -US$112.64m |
| Les revenus | US$321.91m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 17.23 |
| Marge brute | 75.61% |
| Marge bénéficiaire nette | 116.30% |
| Ratio dettes/capitaux propres | 9.2% |
Quelles ont été les performances à long terme de RIGL?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/16 01:47 |
| Cours de l'action en fin de journée | 2026/08/14 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Rigel Pharmaceuticals, Inc. est couverte par 20 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| James Birchenough | Barclays |
| James Birchenough | BMO Capital Markets Equity Research |
| Clarence Powell | BMO Capital Markets Equity Research |